Male hormonal contraception

Handbook of Experimental Pharmacology

Volumn 198, Issue , 2010, Pages 195-221

  Nieschlag, E ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

19nortestosterone; 7alpha methyl 19nortestosterone; Acceptability of male hormonal contraception; Azoospermia; Condoms; Etonogestrel; Gestagens; GnRH analogs; Levonorgestrel; Norethisterone; Suppression of spermatogenesis; Testosterone; Vasectomy

Indexed keywords

CYPROTERONE ACETATE; DESOGESTREL; DIENOGEST; ELCOMETRINE; ETONOGESTREL; FOLLITROPIN; GESTAGEN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADOTROPIN; HYDROXYPROGESTERONE ACETATE; LEVONORGESTREL; LUTEINIZING HORMONE; MEDROXYPROGESTERONE ACETATE; NANDROLONE; NORETHISTERONE; NORETHISTERONE ACETATE; NORETHISTERONE ENANTATE; PLACEBO; TESTOSTERONE; TESTOSTERONE 4 BUTYLCYCLOHEXANECARBOXYLATE; TESTOSTERONE ENANTATE; TESTOSTERONE PROPIONATE; TESTOSTERONE UNDECANOATE; TRESTOLONE;

ACNE; ASIAN; AZOOSPERMIA; CASTRATION; CAUCASIAN; CLINICAL TRIAL; COITUS; CONDOM; DRUG HALF LIFE; DRUG STRUCTURE; FAMILY PLANNING; HEMATOCRIT; HORMONAL CONTRACEPTION; HORMONE INHIBITION; HUMAN; MALE; OLIGOSPERMIA; PRIORITY JOURNAL; RACE DIFFERENCE; REVIEW; SEXUAL BEHAVIOR; SIDE EFFECT; SPERMATOGENESIS; TREATMENT OUTCOME; VASECTOMY; VOLUNTEER; WEIGHT GAIN;

EID: 77956896623     PISSN: 01712004     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-02062-9_11     Document Type: Review

References (92)

1. All Party Parliamentary Group on Population, Development and Reproductive Health (2007) Return of the population growth factor: its impact upon the Millennium Development Goals. House of Commons, London.
2. Alvarez-Sanchez F, Faundes A, Brache V, Leon P (1977) Attainment and maintenance of azoospermia with combined monthly injections of depot medroxyprogesterone acetate and testosterone enanthate. Contraception 15:635-648
3. Anawalt BD, Bebb RA, Bremner WJ, Matsumoto AM (1999) A lower dosage levonorgestrel and testosterone combination effectively suppresses spermatogenesis and circulating gonadotrophin levels with fewer metabolic effects than higher dosage combinations. J Androl 20: 407-414
4. Anawalt BD, Herbst KL, Matsumoto AM, Mulders TM, Coelingh-Bennink HJ, Bremner WJ (2000) Desogestrel plus testosterone effectively suppresses spermatogenesis but also causes modest weight gain and high-density lipoprotein suppression. Fertil Steril 74:707-714
5. Anawalt BD, Amory JK, Herbst KL, Coviello AD, Page ST, Bremner WJ, Matsumoto AM (2005) Intramuscular testosterone enanthate plus very low dosage oral levonorgestrel suppresses spermatogenesis without causing weight gain in normal young men: a randomized clinical trial. J Androl 26:405-413
6. Anderson RA, Baird DT (1997) Progress towards a male pill. IPPF Med Bull 31:3-4
7. Anderson RA, Kinniburgh D, Baird DT (2002a) Suppression of spermatogenesis by etonogestrel implants with depot testosterone: potential for long-acting male contraception. J Clin Endocrinol Metab 87:3640-3649
8. Anderson RA, Van Der Spuy ZM, Dada OA, Tregoning SK, Zinn PM, AdenijiOA FTA, Smith KB, Baird DT (2002b) Investigation of hormonal male contraception in African men: suppression of spermatogenesis by oral desogestrel with depot testosterone. Hum Reprod 17:2869-2877
9. April K, Köster R, Schreiner W (1993) Wie effektiv schutzen Kondome vor einer HIV-Ubertragung? Med Klin 88:304-311
10. Barfield A, Melo J, Coutinho E, Alvarez-Sanchez F, Faundes A, Brache V, Leon P, Frick J, Bartsch G, Weiske WH, Brenner P, Mishell D Jr, Bernstein G, Ortiz A (1979) Pregnancies associated with sperm concentrations below 10 million/ml in clinical studies of a potential male contraceptive method, monthly depot medroxyprogesterone acetate and testosterone esters. Contraception 20:121-127
11. Barfield JP, Nieschlag E, Cooper TG (2006) Fertility control in wildlife: humans as a model. Contraception 73:6-22
12. Bebb RA, Anawalt BD, Christensen RB, Paulsen CA, Bremner WJ, Matsumoto AM (1996) Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone: a promising male contraceptive approach. J Clin Endocrinol Metab 81:757-762
13. Behre HM, Nashan D, Hubert W, Nieschlag E (1992) Depot gonadotropin-releasing hormone agonist blunts the androgen-induced suppression of spermatogenesis in a clinical trial of male contraception. J Clin Endocrinol Metab 74:84-90
14. Behre HM, Baus S, Kliesch S, Keck C, Simoni M, Nieschlag E (1995) Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders. J Clin Endocrinol Metab 80:2394-2403
15. Behre HM, Kliesch S, Lemcke B, Nieschlag E (2001) Suppression of spermatogenesis to azoospermia by combined administration of GnRH antagonist and 19-nortestosterone cannot be maintained by 19-nortestosterone alone in normal men. Hum Reprod 16:2570-2577
16. Behre HM, Wang C, Handelsman DJ, Nieschlag E (2004) Pharmacology of testosterone preparations. In: Nieschlag E, Behre HM (eds) Testosterone: action, deficiency, substitution, 3rd edn. Cambridge University Press, Cambridge, pp 405-444
17. Birg H (2005) 100 Jahre Geburtenruckgang. Frankfurter Allgemeine Zeitung 26.2.2005
18. Brady BM, Walton M, Hollow N, Kicman AT, Baird DT, Anderson RA (2004) Depot testosterone with etonogestrel implants result in induction of azoospermia in all men for long-term contraception. Hum Reprod 19:2658-2667
19. Brenner PF, Mishell DR Jr, Bernstein GS, Ortiz A et al (1977) Study of medroxyprogesterone acetate and testosterone enanthate as a male contraceptive. Contraception 15:679-691
20. Buchter D, von Eckardstein S, von Eckardstein A, Kamischke A, Simoni M, Behre HM, Nieschlag E (1999) Clinical trial of transdermal testosterone and oral levonorgestrel for male contraception. J Clin Endocrinol Metab 84:1244-1249
21. Darroch JE (2008) Male fertility control - where are the men? Contraception 78:S7-S17
22. Engelmann U, Gralla O (2010) Vasectomy and refertilisation. In: Nieschlag E, Behre HM, Nieschlag S (eds) Andrology: male reproductive health and dysfunction, 3rd edn. Springer, Heidelberg, pp 565-576
23. Ersheng G, Cuihong L, Youlun G, Lamei L, Changhai H (1999) Inhibiting effects of sino-implant plus testosterone undecanoate on spermatogenesis in Chinese men. Reprod Contracept 10:98-105
24. Faundes A, Brache V, Leon P, Schmidt F, Alvarez-Sanchez F (1981) Sperm suppression with monthly injections of medroxyprogesterone acetate combined with testosterone enanthate at a high dose (500 mg). Int J Androl 4:235-245
25. Fogh M, Corker CS, McLean H (1980) Clinical trial with levonorgestrel and testosterone enanthate for male fertility control. Acta Endocrinol 95:251-257
26. Frick J, Bartsch G, Weiske WH (1977) The effect of monthly depot medroxyprogesterone acetate and testosterone on human spermatogenesis. II. High initial dose. Contraception 15:669-677 (Pubitemid 8145361)
27. Frick J, Danner C, Kunit G, Joos H, Kohle R (1982) Spermatogenesis in men treated with injections of medroxyprogesterone acetate combined with testosterone enanthate. Int J Androl 5:246-252
28. Gaw Gonzalo IT, Swerdloff RS, Nelson AL, Clevenger B, Garcia R, Berman N, Wang C (2002) Levonorgestrel implants (Norplant II) for male contraception clinical trials: combination with transdermal and injectable testosterone. J Clin Endocrinol Metab 87:3562-3572
29. Grimes DA, Lopez LM, Gallo MF, Halpern V, Nanda K, Schulz KF (2007) Steroid hormones for contraception in men (review). Cochrane Database Syst Rec 004316
30. Gu Y-Q, Wang X-H, Xu D, Peng L, Cheng L-F, Huang M-K, Huang Z-J, Zhang G-Y (2003) A multicenter contraceptive efficacy study of injectable testosterone undecanoate in healthy Chinese men. J Clin Endocrinol Metab 88:562-568
31. Gu YQ, Tong JS, Ma DZ, Wang XH, Yuan D, Tang WH, Bremner WJ (2004) Male hormonal contraception: effects of injections of testosterone undecanoate and depot medroxyprogesterone acetate at eight-week intervals in Chinese men. J Clin Endocrinol Metab 89:2254-2262
32. Gu Y, Liang X, Wu W, Liu M, Song S, Cheng L, Bo L, Xiong C, Wang X, Liu X, Peng L, Yao K (2009) Multicenter contraceptive efficacy trial of injectable testosterone undecanoate in Chinese men. J Clin Endocrinol Metab 94(6):1890-1892
33. Guerin JF, Rollet J (1988) Inhibition of spermatogenesis in men using various combinations of oral progestagens and percutaneous or oral androgens. Int J Androl 11:187-199
34. Gui YL, He CH, Amory JK, Bremner WJ, Zheng EX, Yand J, Yand PJ, Gao ES (2004) Male hormonal contraception: suppression of spermatogenesis by injectable testosterone undecanoate alone or with levonorgestrel implants in Chinese men. J Androl 25:720-727
35. Hair WM, Kitteridge K, Wu FCW (1999) A new male contraceptive pill/patch combination - oral desogestrel and transdermal testosterone: suppression of gonadotropins and spermatogenesis in men. In: The Endocrine Society's 81st Annual Meeting; 1999 June 12-15; San Diego, CA, USA; Poster P3-374
36. Handelsman DJ, Conway AJ, Boylan LM (1992) Suppression of humanspermatogenesis by testosterone implants. J Clin Endocrinol Metab 75:1326-1332
37. Handelsman DJ, Conway AJ, Howe CJ, Turner L, Mackey MA (1996) Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot. J Clin Endocrinol Metab 81:4113-4121
38. Heckel M (1939) Production of oligospermia in a man by the use of testosterone propionate. Proc Soc Exp Biol Med 40:658-659
39. Heinemann K, Saad F, Wiesemes M, White S, Heinemann L (2005) Attitudes toward male fertility control: results of a multinational survey on four continents. Hum Reprod 20:549-556
40. Kamischke A, Nieschlag E (2004) Progress towards hormonal male contraception. Trends Pharmacol Sci 25:49-57
41. Kamischke A, Plöger D, Venherm S, von Eckardstein S, von Eckardstein A, Nieschlag E (2000) Intramuscular testosterone undecanoate with or without oral levonorgestrel: a randomized placebo-controlled feasibility study for male contraception. Clin Endocrinol 53:43-52
42. Kamischke A, Venherm S, Plöger D, von Eckardstein S, Nieschlag E (2001) Intramuscular testosterone undecanoate and norethisterone enanthate in a clinical trial for male contraception. J Clin Endocrinol Metab 86:303-309
43. Kamischke A, Heuermann T, Kruger K, von Eckardstein S, Schellschmidt I, Rubig A, Nieschlag E (2002) An effective hormonal male contraceptive using testosterone undecanoate with oral or injectable norethisterone preparations. J Clin Endocrinol Metab 87:530-539
44. Kinniburgh D, Anderson RA, Baird DT (2001) Suppression of spermatogenesis with desogestrel and testosterone pellets is not enhanced by addition of finasteride. J Androl 22:88-95
45. Kinniburgh D, Zhu H, Cheng L, Kicman AT, Baird DT, Anderson RA (2002) Oral desogestrel with testosterone pellets induces consistent suppression of spermatogenesis to azoospermia in both Caucasian and Chinese men. Hum Reprod 17:1490-1501
46. Knuth UA, Behre HM, Belkien L, Bents H, Nieschlag E (1985) Clinical trial of 19-nortestosteronehexoxyphenylpropionate (Anadur) for male fertility regulation. Fertil Steril 44:814-821
47. Knuth UA, Yeung CH, Nieschlag E (1989) Combination of 19-nortestosterone-hexyoxyphenylpropionate (Anadur) and depot- medroxyprogesterone-acetate (Clinovir) for male contraception. Fertil Steril 51:1011-1018
48. Kornmann B, Nieschlag E, Zitzmann M, Gromoll J, Simoni M, von Eckardstein S (2009) Body fat content and testosterone pharmacokinetics determine gonadotropin suppression after intramuscular injections of testosterone preparations in normal men. J Androl 30:602-613
49. Liu PY, Swerdloff RS, Christenson PD, Handelsman DJ, Wang C (2006) Hormonal male contraception summit group. Rate, extent, and modifiers of spermatogenic recovery after hormonal male contraception: an integrated analysis. Lancet 367:1412-1420
50. Li JW, Gu YQ (2008) Predictors for partial suppression of spermatogenesis of hormonal male contraception. Asian J Androl 10:723-730
51. Liu PY, Swerdloff RS, Anawalt BD, AAnderson RA, Bremner WJ, Elliesen J, Gu YQ, Kersemaekers WM, McLachlan RI, Meriggiola MC, Nieschlag E, Sitruk-Ware R, Vogelsong K, Wang XH, Wu FC, Zitzmann M, Handelsman DJ, Wang C (2008) Determinants of the rate and extent of spermatogenic suppression during hormonal male contraception: an integrated analysis. J Clin Endocrinol Metab 93:1774-1783
52. Martin CW, Anderson RA, Cheng L, Ho PC, van der Spuy Z, Smith KB, Glasier AF, Everington D, Baird DT (2000) Potential impact of hormonal male contraception: crosscultural implications for development of novel preparations. Hum Reprod 15:637-645
53. McLachlan RI, McDonald J, Rushford D, Robertson DM, Garrett C, Baker HW (2000) Efficacy and acceptability of testosterone implants, alone or in combination with a 5alpha-reductase inhibitor, for male hormonal contraception. Contraception 62:73-78
54. McLachlan RI, O'Donnell L, Stanton PG, Balourdos G, Frydenberg M, DeKretser DM, Robertson DM (2002) Effects of testosterone plus medroxyprogesterone acetate on semen quality, reproductive hormones and germ cell populations in normal young men. J Clin Endocrinol Metab 87:546-556
55. Melo JF, Coutinho EM (1977) Inhibition of spermatogenesis in men with monthly injections of medroxyprogesterone acetate and testosterone enanthate. Contraception 15:627-634
56. Meriggiola MC, Bremner WJ, Paulsen CA, Valdiserri A, Incorvala L, Motta R, Pavani A, Capelli M, Flamigni C (1996) A combined regimen of cyproterone acetate and testosterone enanthate as a potentially highly effective male contraceptive. J Clin Endocrinol Metab 81:3018-3023
57. Meriggiola MC, Bremner WJ, Costantino A, Pavani A, Capelli M, Flamigni C (1997) An oral regimen of cyproterone acetate and testosterone undecanoate for spermatogenic suppression in men. Fertil Steril 68:844-850
58. MeriggiolaMC,BremnerWJ,CostantinoA,DiCintioG, FlamigniC(1998) Lowdose of cyproterone acetate and testosterone enanthate for contraception in men. Hum Reprod 13:1225-1229
59. Meriggiola MC, Costantino A, Bremner WJ, Morselli-Labate AM (2002) Higher testosterone dose impairs sperm suppression induced by a combined androgen-progestin regimen. J Androl 23:684-690
60. Meriggiola MC, Costantino A, Cerpolini S, Bremner WJ, Huebler D, Morselli-Labate AM, Kirsch B, Bertaccini A, Pelusi C, Pelusi G (2003) Testosterone undecanoate maintains spermatogenic suppression induced by cyproterone acetate plus testosterone undecanoate in normal men. J Clin Endocrinol Metab 88:5818-5826
61. Meriggiola MC, Costantino SF, D'Emidio L, Morselli Labate AM, Bertaccini A, Bremner WJ, Rudolph I, Ernst M, Kirsch B, Martorana G, Pelusi G (2005) Norethisterone enanthate plus testosterone undecanoate for male contraception: effects of various injection intervals on spermatogenesis, reproductive hormones, testis, and prostate. J Clin EndocrinolMetab 90:2005-2014
62. Meriggiola MC, Cerpolini S, Bremner WJ, Mbizvo MT, Vogelsong KM, Martorana G, Pelosi G (2006) Acceptability of an injectable male contraceptive regimen of norethisterone enanthate and testosterone undecanoate for men. Hum Reprod 21:2033-2040
63. Mommers E, Kersemaeker WM, Elliesen J, Kepers M, Apter D, Behre HM, Beynon J, Bouloux PM, Costantino A, Gerbershagen HP, Gronlund L, Heger-Mahn D, Huhtaniemi I, Koldewihn EL, Lange C, Lindenberg S, Meriggiola MC, Meuleman E, Mulder PFA, Nieschlag E, Perheentupa A, Solomon A, Vaisala L, FC W, Zitzmann M (2008) Male hormonal contraception: a double-blind, placebo-controlled study. J Clin Endocrinol Metab 93:2572-2580
64. Nieschlag E (2006) Testosterone treatment comes of age: new options for hypogonadal men. Clin Endocrinol 65:275-281
65. Nieschlag E (2009) Male hormonal contraception: love's labour's lost? J Clin Endocrinol Metab 94:1890-1892
66. Nieschlag E, 10th Summit Meeting Group (2007) 10th Summit Meeting on consensus: recommendations for regulatory approval for hormonal male contraception. October 22-23, 2006. Contraception 75:166-167
67. Nieschlag E, Behre HM (2010) Approaches to hormonal male contraception. In: Nieschlag E, Behre HM, Nieschlag S (eds) Andrology: male reproductive health and dysfunction, 3rd edn. Springer, Heidelberg, pp 577-587
68. Nieschlag E, Hoogen H, Bölk M, Schuster H, Wickings EJ (1978) Clinical trial with testosterone undecanoate for male fertility control. Contraception 18:607-614 (Pubitemid 9098602)
69. Nieschlag E, Kamischke A, Behre HM (2004) Hormonal male contraception: the essential role of testosterone. In: Nieschlag E, Behre HM (eds) Testosterone: action, deficiency, substitution, 3rd edn. Cambridge University Press, Cambridge, pp 685-714
70. Nieschlag E, Behre HM, Wieacker P, Meschede D, Kamischke A, Kliesch S (2009) Disorders at the testicular level (chap. 13). In: Nieschlag E, Behre HM, Nieschlag S (eds) Andrology: male reproductive health and dysfunction, 3rd edn. Springer, Heidelberg
71. Page ST, Amory JK, Anawalt BD, Irwig MS, Brockenbrough AT, Matsumoto AM, Bremner WJ (2006) Testosterone gel combined with depomedroxyprogesterone acetate is an effective male hormonal contraceptive regimen and is not enhanced by the addition of a GnRH antagonist. J Clin Endocrinol Metab 91:4374-4380
72. Page ST, Amory JK, Bremner WJ (2008) Advances in male contraception. Endocr Rev 29: 465-493
73. Pangkahila W (1991) Reversible azoospermia induced by an androgen-progestin combination regimen in Indonesian men. Int J Androl 14:248-256
74. Pöllanen P, Nikkanen V, Huhtaniemi I (2001) Combination of subcutaneous levonorgestrel implants and transdermal dihydrotestosterone gel for male hormonal contraception. Int J Androl 24:369-380
75. Qoubaitary A, Meriggiola C, Ng CM, Lumbreras L, Cerpolini S, Pelusi G, Christensen PD, Hull L, Swerdloff RS, Wang C (2006) Pharmacokinetics of testosterone undecanoate injected alone or in combination with norethisterone enanthate in healthy men. J Androl 27:853-867
76. Strauss JF, Chaudhuri G (2007) The accelerated pace of pharma abandonment of research and development in family planning and fertility: will reproductive health technology be frozen in time? Fertil Steril 87:717-718
77. Swerdloff RS, Bagatell CJ, Wang C, Anawalt BD, Berman N, Steiner B, Bremner WJ (1998) Suppression of spermatogenesis in man induced by Nal-Glu gonadotropin releasing hormone antagonist and testosterone enanthate (TE) is maintained by TE alone. J Clin Endocrinol Metab 83:3527-3533
78. Turner L, Conway AJ, Jimenez M, Liu PY, Forbes E, McLachlan RI, Handelsman DJ (2003) Contraceptive efficacy of a depot progestin and androgen combination in men. J Clin Endocrinol Metab 88:4659-4667
79. von Eckardstein S, Schmidt A, Kamischke A, Simoni M, Gromoll J, Nieschlag E (2002) CAG repeat length in the androgen receptor gene and gonadotrophin suppression influence the effectiveness of hormonal male contraception. Clin Endocrinol 57:647-655
80. von Eckardstein S, Noe G, Brache V, Nieschlag E, Croxatto H, Alvarez F, Moo-Young A, Sivin I, Kumar N, Small M, Sundaram K, International Committee for Contraception Research, The Population Council (2003) A clinical trial of 7 alpha-methyl-19-nortestosterone implants for possible use as a long-acting contraceptive formen. J Clin Endocrinol Metab 88:5232-5239
81. Waites GMH (2003) Development of methods of male contraception: impact of the World Health Organization task force. Fertil Steril 80:1-15
82. Walton MJ, Kumar N, Baird DT, Ludlow H, Anderson RA (2007) 7a-methyl-19-nortestosterone (MENT) vs testosterone in combination with etonogestrel implants for spermatogenic suppression in healthy men. J Androl 28:679-688
83. Wang C, Wang XH, Nelson AL (2006) Levonorgestrel implants enhanced the suppression of spermatogenesis by testosterone implants: comparison between Chinese and non-Chinese men. J Clin Endocrinol Metab 91:460-470
84. Wang C, Cui YG, Wang XH, Jia Y, Hikim AS, Lue YH, Tong JS, Qian LX, Sha JH, Zhou ZM, Hull L, Leung A, Swerdloff RS (2007) Transient scrotal hyperthermia and levonorgestrel enhance testosterone-induced spermatogenesis suppression in men through increased germ cell apoptosis. J Clin Endocrinol Metab 92:3292-3304
85. WHO (2005) Controlled trials register NET-EN plus TU as a male contraceptive (WHO-HRP ID A25165). http://www.who.int/reproductive-health/rhl/ a25165.html. Accessed 29 Nov 2005
86. World Health Organization Task Force on Methods for the Regulation of Male Fertility (1990) Contraceptive efficacy of testosterone-induced azoospermia in normal men. Lancet 336:955-959
87. World Health Organization Task Force on Methods for the Regulation of Male Fertility (1993) Comparison of two androgens plus depot-medroxyprogesterone acetate for suppression to azoospermia in Indonesian men. Fertil Steril 60:1062-1068
88. World Health Organization Task Force on Methods for the Regulation of Male Fertility (1996) Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men. Fertil Steril 65:821-829
89. Wu FC, Aitken RJ (1989) Suppression of sperm function by depot medroxyprogesterone acetate and testosterone enanthate in steroid male contraception. Fertil Steril 51:691-698
90. Wu FCW, Balasubramanian R, Mulders TMT, Coelingh-Bennink HJT (1999) Oral progestogen combined with testosterone as a potential male contraceptive: additive effects between desogestrel and testosterone enanthate in suppression of spermatogenesis, pituitary-testicular axis, and lipid metabolism. J Clin Endocrinol Metab 84:112-122
91. Zhang GY, Gu YQ, Wang XH, Cui YG, Bremner WJ (1999) A clinical trial of injectable testosterone undecanoate as a potential male contraceptive in normal Chinese men. J Clin Endocrinol Metab 84:3642-3647
92. Zhang L, Shal IH, Liu Y, Vogelsong KM, Zhang L (2006) The acceptability of an injectable, oncea-month male contraceptive in China. Contraception 73:548-553